Recently, The Galien Foundation announced the nominees for the 2025 Prix Galien USA award. Thanks to its continuous research and development achievements and clinical application performance in the field of artificial heart and life support technology, Xinqing Medical has successfully been shortlisted for the "Best Start Up" award. This award is recognized as one of the most influential honors in the global life sciences and medical technology field, aimed at recognizing scientific innovations that can significantly improve human health.
Internationally recognized life science awards
The Prix Galien Prize was established in 1970 and named after Galen, the father of modern medicine. For over 50 years, it has been dedicated to promoting global medical innovation and is known as the "Nobel Prize in the field of biomedicine".
Since its establishment in 2007, Prix Galien USA has been evaluated by a panel of Nobel laureates and internationally renowned medical experts based on core dimensions such as scientific innovation, clinical value, and patient benefits, without being affected by commercialization or market size. Previous winners include Novartis' CAR-T therapy Kymriah® Abbott's Mitral Clip® Cardiac intervention devices have led the transformation of treatment models in their respective fields.
Bruno Cohen, President of the Galen Foundation, said, "The progress in the field of life sciences over the past year has been exciting, and these nominated projects demonstrate the accelerating trend of medical innovation and bring hope to future patients
2025 Nomination Highlights
In 2025, Prix Galien USA has established four award categories: Best Digital Health Solution, Best Medical Technology, Incubator/Accelerator and Equity Support, and Best Start up Enterprise, with nominated companies covering innovative forces worldwide. Renowned companies such as Abbott, Empatica, Recursion, Oura, etc. are also on the nomination list, demonstrating the level of competition and industry standards this year.
In the "Best Startup" category, 53 emerging companies were shortlisted, covering cutting-edge fields such as artificial intelligence assisted diagnosis and treatment, advanced medical devices, cell and gene therapy, wearable monitoring, etc.
The technology and clinical value behind the nomination
Xinqing Medical has long been committed to the research and development of artificial hearts and full process life support platforms. Its core products include:
• MoyoAssist® Extracorporeal VAD: It has been applied in many large tertiary hospitals in China, providing stable circulatory support for high-risk PCI, acute heart failure, and complex cardiovascular surgery patients, improving intraoperative hemodynamics, and buying valuable time for patients waiting for organ transplantation or cardiac function recovery.
• NyokAssist® The Percutanous VAD (Foldable, Minimally Invasive Path Intervention Short term Assist Device): With its innovative design and minimally invasive advantages, it has brought new possibilities for short-term cardiac assisted therapy and has been recognized as an FDA Breakthrough Device, bringing potential significant clinical benefits to critically ill patients.
• BreathMo® Portable magnetic levitation extracorporeal membrane oxygenation (ECMO) system: The fully magnetic levitation system provides better blood compatibility, with dual indications of extracorporeal ventricular assist and extracorporeal membrane oxygenation, approaching the lung function of the human body itself.
International Influence and Future Prospects
Being nominated for the Prix Galien USA Award in 2025 means that ASRock Medical's technological roadmap, clinical achievements, and development potential have been recognized by international experts.
The 2025 Prix Galien USA Awards ceremony will be held on October 30th at the American Museum of Natural History in New York, bringing together top medical technology innovators from around the world to witness the birth of the annual award-winning projects.
Xinqing Medical will continue to be driven by scientific innovation, promote the research and application of artificial hearts and life support platforms, and strive to provide safer, more efficient, and accessible treatment options for critically ill patients worldwide.